The expression of urokinase type plasminogen activator is a novel prognostic factor in Dukes B and C colorectal cancer

Oncology Reports

Volumn 5, Issue 2, 1998, Pages 431-435

  Kim, Seung Jin ^a   Shiba, Eiichi ^a   Tsukamoto, Fumine ^a   Izukura, Masaakj ^a   Taguchi, Tetsuya ^a   Yoneda, Kohri ^a   Tanji, Yoshio ^a   Kimoto, Yasuhiko ^a   Takai, Shin Ichiro ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Dukes B and C colorectal cancer; Immunohistochemistry; Prognostic factor; u PA

Indexed keywords

UROKINASE;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 13144268557     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.2.431     Document Type: Article

References (31)

1. Duffy MJ: The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10: 145-155, 1992.
2. Duffy MJ: Urokinase-type plasminogen activator and malignancy. Fibrinolysis 7: 295-302, 1993.
3. Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L and Graeff H: Tumor-associated urokinase type plasminogen activator: Biological and clinical significance. Biol Chem Hoppe-Seyler 373: 611-622, 1992.
4. Buo L, Meling GR, Karlsrud TS, Johansen HT and Aasen AO: Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Hum Pathol 26: 1133-1138, 1995.
5. Tan K, Powe DG, Gray T, Turner DR and Hewitt RE: Regional variations of urokinase-type plasminogen activator in human colorectal cancer: A quantitative study by image analysis. Int J Cancer 60: 308-314, 1995.
6. Verspaget HW, Sier CFM, Ganesh S, Griffioen G and Lamers CBHW: Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 31 A: 1105-1109, 1995.
7. Gandolfo GM, Conti L and Vercillo M: Fibrinolysis components as prognostic marker in breast cancer and colorectal carcinoma. Anticancer Res 16: 2155-2159, 1996.
8. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP and Sheahan K: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 344: 583-584, 1994.
9. Sato T, Nishimura G, Yonemura Y, Nojima N, Ninomiya I, Fujimura T, Sugiyama K, Miwa K, Miyazaki I, Nonomura A and Yamaguchi Y: Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 52: 347-352, 1995.
10. Kim SJ, Shiba E, Taguchi T, Inoue T, Tanji Y, Kimoto Y, Izukura M and Takai S: Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res 17: 1373-1378, 1997.
11. Japanese Research Society for Cancer of Colon and Rectum: General Rules for Clinical and Pathological Studies on Cancer of Colon, Rectum and Anus. Kanehara Publication, Tokyo, 1985.
12. Dano K, Behrendt N, Brunner N, Ellis V, Ploug M and Pyke C: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8 (Suppl): 189-203, 1994.
13. Janicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530, 1994.
14. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Bontenbal M, Janicke F and Klijn JGM: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52: 6101-6105, 1992.
15. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ and Andreasen PA: Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 74: 2276-2280, 1994.
16. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U and Siewert JR: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54: 2900-2907, 1994.
17. Ganesh S, Sier CFM, Heerding MM, van Krieken JHJM, Griffioen Gerrit, Welvaart K, van de Velde CJH, Verheijen JH, Lamers CBHW and Verspaget HW: Prognostic value of the plasminogen activator system in patients with gastric carcinoma. Cancer 77: 1035-1043, 1996.
18. Cho JY, Chung HC, Noh SH, Roh JK, Min JS and Kim BS: High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma. Cancer 79: 878-883, 1997.
19. Ganesh S, Sier CFM, Griffioen G, Vloedgraven HJM, Boer A, Welvaart K, van de Velde CJH, van Krieken JHJM, Verheijen JH, Lamers CBHW and Verspaget HW: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 54: 4065-4071, 1994.
20. Foekens JA, Look MP, Peters HA, van Putten WLJ, Portengen H and Klijn JGM: Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87: 751-756, 1995.
21. Blasi F: Surface receptors for urokinase plasminogen activator. Fibrinolysis 2: 73-84, 1988.
22. Moller LB: Structure and function of the urokinase receptor. Blood Coagul Fibrinolysis 4: 293-303, 1993.
23. Blasi F, Conese M, Moller LB, Pedersen N, Cavallaro U, Cubellis MV, Fazioli F, Hernandez-Marrero L, Limongi P, Munoz-Canoves P, Resnati M, Riittinen L, Sidenius N, Soravia E, Soria MR, Stoppelli MP, Talarico D, Teesalu T and Valcamonica S: The urokinase receptor: Structure, regulation and inhibitor-mediated internalization. Fibrinolysis 8 (Suppl): 182-188, 1994.
24. Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch K-W, Loehrs U and Schildberg FW: Tumor-associated proteolysis and prognosis: New functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 13: 2084-2093, 1995.
25. Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L and Dano K: Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24: 131-138, 1994.
26. Ohtani H, Pyke C, Dano K and Nagura H: Expression of urokinase receptor in various stromal-cell populations in human colon cancer: immunoelectron microscopical analysis. Int J Cancer 62: 691-696, 1995.
27. Tsuchiya A, Ando Y, Kikuchi Y, Kanazawa M, Sato H and Abe R: Venous invasion as a prognostic factor in colorectal cancer. Surg Today 25: 950-953, 1995.
28. Deans GT, Patterson CC, Parks TG, Spence RA, Heatley M, Moorehead RJ and Rowlands BJ: Colorectal carcinoma: importance of clinical and pathological factors in survival. Ann R Coll Surg Engl 76: 59-64, 1994.
29. Leite JF, Granjo ME, Martins MI, Reis RC, Monteiro JC and Castro-Sousa F: Effect of perioperative blood transfusions on survival of patients after radical surgery for colorectal cancer. Int J Colorectal Dis 8: 129-133, 1993
30. Takahashi T, Kato T, Kodaira S, Koyama Y, Sakabe T, Tominaga T, Hamano K, Yasutomi M and Ogawa N: Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy. Am J Clin Oncol 19: 408-415, 1996.
31. Newland RC, Dent OF, Lyttle MN, Chapuis PH and Bokey EL: Pathologic determinants of survival associated with colorectal cancer with lymph node metastases. A multivariate analysis of 579 patients. Cancer 73: 2076-2082, 1994.